This product is a CRISPR/Cas9-mediated ARGLU1 knockout polyclonal HeLa cell population. The polyclonal format provides a heterogeneous pool of edited cells, each harboring targeted disruption of the ARGLU1 gene. This loss-of-function model enables investigation of ARGLU1’s roles in pre-mRNA splicing and estrogen signaling without the homogeneity of clonal lines. It is suitable for bulk functional assays in cancer biology and RNA processing research.
HeLa cells are a widely used human cervical epithelial cell line derived from an HPV18-positive adenocarcinoma. They exhibit robust estrogen receptor signaling and active gene expression programs, making them an appropriate host for studying ARGLU1. Their aneuploidy and cancer cell properties provide a context relevant to oncogenic processes, particularly those driven by estrogen receptor pathways.
ARGLU1 encodes a splicing factor and estrogen receptor coactivator. It interacts with spliceosomal components such as SNRNP70 and SRSF1, and associates with estrogen receptor alpha (ESR1) to modulate transcription. Upstream, the estrogen-ESR1 complex activates ARGLU1, which in turn promotes expression of downstream targets including TFF1 and PGR, while also regulating alternative splicing of numerous transcripts. Representative pathway components include SNRPA and U2AF2, underscoring its integration into both spliceosomal machinery and ESR1 transcriptional complexes.
In HeLa cells, ARGLU1 contributes to estrogen receptor-mediated transcriptional programs and alternative splicing outcomes, directly linked to cervical cancer biology. Because HeLa cells express HPV oncogenes and ESR1, disruption of ARGLU1 disrupts estrogen-responsive gene networks that sustain proliferation and survival. This polyclonal knockout pool allows dissection of ARGLU1’s dual functions in splicing and transcription without clonal artifacts, providing a physiologically relevant model.
Researchers can employ this model for alternative splicing analysis via RNA-seq, RT-qPCR, and western blotting to assess splice variant changes and protein expression. Co-immunoprecipitation and luciferase reporter assays enable studies of ARGLU1-ESR1 interactions and transcriptional activity. Immunofluorescence can localize ARGLU1 within nuclear compartments. Typical applications include estrogen signaling studies, functional genomics of splicing, and drug response testing in estrogen receptor-positive cancers. For further information, please contact Ascent Research.
